ASRM 2011 Updates

In addition to the magical wonders of Disney, Orlando welcomed reproductive endocrinologists from around the world this October to attend the annual meeting of The American Society for Reproductive Medicine (ASRM).  Several members of Pacific Fertility Center were among the participants. 

Preimplantation Genetic Screening (PGS)

PGS was again a hot topic of discussion.  Multiple presentations showcased the recent technological advances in this field.  The ability to perform comprehensive chromosome analysis using microarray technology instead of the first generation method of FISH (fluorescent in situ hydridization), which could only test a selected number of chromosomes at a time, has increased the accuracy and the detection rate of embryonic aneuploidy (abnormal number of chromosomes).  Laboratory advances such as biopsy of the trophectoderm (the outer cell layer of a day 5 embryo) and vitrification (a method of rapid cooling of embryos that minimizes ice crystal formation) have further improved success.  As the result of the above-mentioned technical breakthroughs, we have seen a measurable increase in the pregnancy rate and a decrease in the miscarriage rate from IVF using PGS.  Additionally, two respected groups independently presented data supporting the use of PGS as a successful embryo selection tool to promote elective single embryo transfer (the process of transferring one embryo at a time into the uterus to reduce the risks of multiple gestation).  The pregnancy rates from a single PGS-selected euploid embryo were 58% and 60.7% compared to 42% and 40.7%, respectively, from a morphologically comparable but non-PGS-selected embryo.  Moreover, the miscarriage rates decreased to 6% and 6.3% from 12% and 12.5%, respectively.  The risk of multiple gestation was essentially eliminated (1-2% monozygotic twining).

We were excited to note the parallels between the data presented and our own work at PFC.  Several years ago, we made the commitment towards decreasing our multiple pregnancy rates by adopting a policy of encouraging elective single embryo transfer in qualified patients.  We have found that 24-chromosome aneuploidy screening (via informatics-based single nucleotide polymorphism microarray technology by Gene Security Network) of trophectoderm biopsy has significantly enhanced our ability to select the embryo with the best implantation potential.  Our improved vitrification program has also allowed us to reassure our patients that their unused embryos can be safely stored for future use, thus removing the pressure to transfer more embryos at one setting.  We are very proud of our success so far in achieving our goal as we are currently the number one ranked program in the nation of the fewest number of embryos transferred in donor cycles (1.4 embryos per fresh cycle) while maintaining a high pregnancy rate of 57% (of all programs with more than 20 donor cycles per year, 2009 SART).  For more details on our experience with single embryo transfer and its pregnancy rates, please read “What are my chances of having a baby from a single IVF cycle” by our embryologist, Erin Fischer, and laboratory director, Dr. Joe Conaghan, in this issue of Fertility Flash.

Fertility Preservation

Another interesting topic that deserves attention is fertility preservation using oocyte cryopreservation. Two centers with extensive experience in this area shared their outcome data from both methods of cryopreservation, slow freeze and vitrification.  A center in Atlanta vitrified over 2000 oocytes from donors with an average age of 26 years.  Of the 1772 oocytes rewarmed, 88% survived, 75% fertilized, and 51% resulted in viable cleavage stage (day 3) embryos.  Live birth rate per cryopreserved oocyte was 11%.  The other presentation by a group in New York reported their experience of rewarming 536 cryopreserved oocytes using both slow freeze and vitrification from non-donors with an average age of 32 years.  The overall live birth rate per rewarmed oocyte was 5.5%.  Study is ongoing to compare the efficacies of slow freeze and vitrification.     

PFC’s own data with vitrification of oocytes is comparable to, if not better than, the results presented at our national meeting by various groups across the US.  A 5-10% live birth rate per oocyte in women under the age of 35 years translates to a respectable chance of having a baby in the future from one to two treatment cycles in the present (10-20 oocytes can be expected to be cryopreserved per cycle).   As we further perfect our own techniques of vitrification, we will be increasingly more confident in our ability to offer young women with a viable option for future family planning in addition to embryo freezing and donor gametes.  Future research is needed to achieve the same type of success rates in older women.   

Participating at ASRM is always an educational experience.  We enjoyed sharing our own clinical and research endeavors with our colleagues across the US and all over the world.  Our position as the nation’s leader in many of the most cutting-edge technologies in our field is a validation of our commitment to excellence and to provide our patients with the highest quality care available.

Article originally written by Erica Reder and was published in The New Fillmore.  Article was slightly shortened for length.  To read the complete article and to see pictures, click here.

It’s 7:30 on a Tuesday evening, and nearly every seat in Dino’s Pizza at the corner of Fillmore and California is taken. Couples and families crowd the tables, sharing pizzas, draft beers and sodas. Three television screens broadcast the Tennessee-Vanderbilt basketball game, while mob movie stills and portraits of famous athletes stare out from the walls.

But the newest decoration hangs from the balcony. It’s a blue blanket that proclaims: “BABY BOY.”

Owner Dino Stavrikikis struts among the diners, his photo-loaded iPhone at the ready. Customers gush over pictures of the month-old baby named Santino, while the proud father regales them with tales from the crib. “I really love talking about this story,” says Dino, who’s on a first name basis with nearly everyone in the neighborhood. “I talk about it 10 times a day.”

Santino Vasili Stavrikikis was born on January 22. But the story began a year and a half ago, when the 50-year-old bachelor set his sights on becoming a father.

“There wasn’t one specific day that it hit me and I said, ‘Okay, this is what I need to do,’ ” says Dino. “It was just at this point in my life — you know, you get a little older.”

When the idea of having a son took root, he turned to his customers for advice. “I don’t know what anyone does for a living, but everyone does something,” he says. “So I was kind of throwing out words here and there, and hoping someone would hear me and say, ‘This is where you need to go.’ ”

That moment occurred in August 2009 when friends of Dr. Carl Herbert, a fertility specialist and president of the Pacific Fertility Center, came to Dino’s for dinner. “I started talking about it,” Dino recalls. “They all just stopped eating and said, ‘We have the guy for you.’ ”

Still, Dino admits he had a steep learning curve. “I didn’t know what a surrogate was, I didn’t know what an egg donor was,” he says. “I just kind of knew something about the process.”

And the options seemed overwhelming. He had to choose both an egg donor and a surrogate mother.

But other variables would prove beyond his control. “In January of 2010, within three days my egg donor and carrier fell apart,” says Dino. “I had to start the process all over, start the finances all over. But not once did I think it wasn’t going to happen.”

After losing two egg donors to failed tests, Dino met his best match yet. “Once I met her, I knew she was the right one,” he says of his third, and actual, egg donor.

Searching for a surrogate mother, Dino found the winning combination in a Southern California woman named Dusty Kenney. “We clicked right away,” he says.

Kenney agrees. “I feel really blessed that we found each other because we have such a good connection,” she says. Kenney has a daughter of her own, but she too was new to the world of surrogate pregnancies.

She and Dino kept in close contact throughout her pregnancy, which resulted from the implantation of the donor’s egg fertilized by his sperm. “He would call and check on me probably every other day,” she says. “He would fly down all the time and hang out and he would cook me dinner. He was supportive through the whole process.”

Dino had planned to visit more often as Santino’s February 23 due date approached. “I was going to fly down there on the 15th of February and check into a hotel and just wait it out,” he says. But as it happened, everyone was caught off guard when Santino arrived a month early.

“I got the phone call on the 22nd at 5 in the morning,” Dino recalls. He was there when Santino made his appearance that afternoon at 5:18 at Cedars-Sinai Medical Center in Beverly Hills.

It completely changed Dino’s life. A man who says he had “never lived with anybody” acquired not one but two new roommates: his baby son and a live-in nanny. “She’s phenomenal,” he says of the nanny. “We’ve really gotten along, and we’re making it work.”

They weren’t so sure a month ago when Dino and the nanny brought Santino up from Los Angeles. “We got home at 6 o’clock on Thursday night,” he recalls, “and we just looked at each other like, ‘Now what?’ It forced us to get into fifth gear right away.”

Santino’s temperament makes things easier. “He’s really patient,” says Dino. “He’s a good sport.”

His surrogate mother agrees. “He just has such a calm, sweet personality,” says Kenney. “He doesn’t cry unless he’s hungry.” She has visited Dino and Santino since the birth, and expects to continue to make regular visits. “I imagine I’ll see them once a month,” she says.

Kenney also has thought ahead. “I would imagine it would be like the role of an aunt,” she says. “I just want to be there for him. I think the more fans a child has when growing up the better.”

The egg donor has yet to meet Santino, but Dino expects that she will. “She lives in Florida, but she wanted to be involved as much as she could,” he says.

In the meantime, Santino gets plenty of attention. “Every day he gets two or three presents from around the world,” says Dino. “Everybody comes in and asks for him. It’s turned out, he’s not my son; I’m his father.”

Those who have yet to meet Santino will have ample opportunity when they stop by for pizza. “I want to bring him more and more and more,” Dino says. “But he’s got to get a little bigger.”

Until then, a message painted on the restaurant windows announces to customers and passersby alike: “Santino has arrived.”

Dino says he plans to take down the signs after Santino’s 40-day blessing, a Greek Orthodox rite that will take place in early March. And he’s already dreaming of Santino’s future. “He’ll definitely be working at Dino’s when he’s really young,” says Dino, “just kind of walking around and helping me out.”

For now, father and son see each other mainly outside of the restaurant. “I have to work,” says Dino, “but my schedule’s really flexible.”

The two have already created some memorable moments. “On Saturday, we hung out and watched The Godfather,” Dino says. In the film, Santino is the first-born son of New York Mafia boss Vito Corleone — and the name, which means “little saint” in Italian, stuck with Dino when he first saw The Godfather 35 years ago.

“Dino means ‘the sword,’ ” says Dino. “So it’s the sword and the little saint, which to me means we’re basically watching each other’s back.”

Empowering a woman’s choice using fertility preservation

Protecting and preserving fertility is a new way of empowering reproductive choice. The fertility of youth is no longer a limited resource, constrained by age.  Women can now pursue their reproductive lives at their own pace, rather than according to the obligations of biology.  Reproductive choice means having children when you want them, rather than when you must have them.

Fertility preservation, specifically egg freezing, is changing the way we think about building families.  Through fertility preservation, eggs can be stored and saved for use a later. 

The potential of fertility preservation replaces the tick of the biological clock

The tick-tock of the biological clock influenced reproductive choice in the last decades.  The sacrifice of delaying family while assembling a career, home, and relationship worked in an economic sense.  It did not, however, fit well with the designs of biology. 

Eggs work best at a young age, when there are more of them, and they are more vital. The best pregnancy rates occur in women ages 18-30.  With declining egg numbers and egg quality, pregnancy rates are lower in older age groups, while miscarriage rates and chromosome defects become more common.

Biology wastes eggs

The limit of egg quantity and quality is a consequence of our biology. From mid-gestation through menopause, there is a continuous stream of egg follicles that grow to a certain stage and then are lost.  This pool of eggs is never replenished. Each woman is born with a set number of eggs (over a million), and by puberty perhaps 300,000 remain. Ovulation will happen only 500 times in a woman’s reproductive years. and will result in a child less than 1% of the time.  From start (gestation) to finish (menopause), 1 in a million eggs results in a child.  This constant and dynamic process of decline continues through the reproductive years, uninterrupted by birth control pills, pregnancy or ovulation.

Fertility preservation provides the potential for protection against future infertility

Fertility preservation is a relatively simple process.  The first step is for a woman to see her fertility doctor for an ultrasound and physical exam.  On ultrasound the ovaries are measured and the number of follicles determined.  A treatment calendar with a schedule of injectable fertility drugs is initiated.

Using fertility medications for approximately ten days, multiple eggs begin to mature in the ovaries.  Under sedation, the eggs are retrieved, a process that takes about 10-15 minutes.  The eggs are then cryopreserved and placed in frozen storage.

At a later time, the eggs can be thawed, inseminated with sperm (ICSI is recommended), and the embryo(s) created transferred back into the uterus to develop into a pregnancy.

Technology of Fertility Preservation is improving

We are continuing to optimize the outcomes of oocyte cryopreservation.  In a series of women under age 30 where eggs were cryopreserved, egg survival was 88%.  Over half of the eggs fertilized, and two thirds of transfers resulted in pregnancy.  As of January 2011 Pacific Fertility Center has 8 delivered babies from cryopreserved eggs.

The limits of biology continue to constrain outcomes of those eggs that survive.  Not all eggs have the capacity to produce a viable embryo.  This variable is very age dependent.  In a healthy woman under the age of 30, approximately one third of her eggs(33%) are capable of producing a viable embryo.  In women over the age 40, this ratio changes to one in twenty (5%).

Fertility Preservation:  reproductive choice

The message is this:  Fertility is optimal in your youth.  If you have not started your family, you should consider freezing your eggs for use in the future.

-Philip Chenette, M.D.

The field of Assisted Reproduction has always been one of rapidly evolving technologies, but nowhere more so than in the area of screening embryos. Screening is possible for not only genetic disease (PGD) and but also abnormal numbers of chromosomes (PGS). Along with the revolution in human DNA biotechnology, new companies such as Gene Security Network of Redwood City, California have emerged.  They are able to apply information from the Human Genome Project to the analysis of DNA from single human embryonic cells.

It is now possible to accurately diagnose most any human genetic disease in a pre-implantation human embryo. We do not even need to know the mutated sequence as long as there is DNA available from the parents that carry the mutation. By using what are called “linked markers”, we can make an analysis from the amplified DNA from a single embryonic cell and compare it to the parental DNA to determine the likelihood that any one embryo received mutated copies from either parent. This analysis is done at the time of an IVF cycle when the embryos are in the IVF laboratory. Affected embryos carrying mutations that may cause the disease, such as cystic fibrosis or muscular dystrophy, are not transplanted back into the mother’s uterus.

Until recently, a single embryonic cell could only be analyzed for either a mutated gene sequence using a limited number of markers (usually about 10) or for chromosome copy number (karyotype), but not both at the same time. In the last year, Gene Security Network has offered testing of DNA for BOTH genetic mutations (when parents are at risk for having affected offspring) AND for chromosome copy number to rule out Down Syndrome, Trisomy 18, or any other “aneuploidies” that can cause implantation failure or miscarriage. Both tests can be done on the amplified DNA from a single cell. Pacific Fertility Center has been participating in their pilot studies on this project and, due to the success of the initial group of patients PFC is now offering this type of testing routinely to couples that need this service. We welcome this change because it means we can now not only select unaffected embryos, but also have a fairly high confidence that the embryos we select for embryo transfer have normal chromosome copy numbers and will have a good chance of establishing a normal pregnancy.

Another area in which this DNA micro-array technology has found application is in the area of testing miscarriages for chromosome copy number. In the past, if we wanted to know if the reason a miscarriage had occurred was due to abnormal chromosomes, we had to do a D&C procedure, obtain placental DNA and send it to a cytogenetics lab. At the cytogenetics lab, the placental tissue had to be put into cell culture to try to capture dividing cells, which is the only way a karyotyping analysis could be performed. If the placental tissue contained no viable, living cells, the culture would fail and there would be no results. If the analysis revealed a 46 XX karyotype, we could not be sure that this was a normal female miscarried or if the cell culture was contaminated with maternal DNA. Now we can send the placental tissue with a sample of the mother’s blood, and the lab can tell if the DNA is maternal or not and the tissue does not need to be viable to get a result. This then allows us to determine if a pregnancy loss was due to abnormal fetal chromosomes, one of the most common causes of miscarriage.

There is no doubt that all of these new genetic technologies will continue to evolve over time, becoming even more rapid and accurate than they are today. It is exciting to be involved with applying the latest science and biotech has to offer to help solve clinical problems for our fertility patients.

-Carolyn Givens, M.D.

Since March of 2007, PFC has been vitrifying embryos.  We have now completed over 600 warming cycles, utilizing those embryos.  Vitrification is proving to be a very reliable technology to preserve any unused embryos that remain after a fresh transfer. We continue to adjust our technique and thus increase the successful results of vitrification.  Last year, we introduced a modification to the procedure that allows us to remove the fluid from the cavity in a blastocyst before we begin vitrifying.  As with any freezing procedure, cell water must be substantially removed and replaced with cryoprotectants to avoid ice formation in the cells.  Five and 6 day old embryos, or blastocysts, can have a large fluid filled cavity that slows dehydration and passage of cryoprotectant into the cells.  Since vitrification is an ultra-rapid freezing procedure, any delays caused by the fluid in the cavity may affect the ability of the embryo to survive the procedure.  By making a small breach between two of the outer cells in the embryo, we are now allowing the cavity to collapse prior to beginning the vitrification procedure.  This artificial collapsing has further enhanced results.  We are seeing implantation rates with warmed embryos that are very similar to those achieved with fresh embryos.

Overall, from 636 warming cycles, we have achieved 284 clinical pregnancies (45%) in all age groups combined.  In younger patients (maternal age under 35), there were 103 successful clinical pregnancies from 190 transfers (54%) with an average of just 1.7 embryos transferred.  This pregnancy rate drops to 42% (41/97) in 36-37-year-old patients with an average transfer of 1.8 embryos.  In the 38-40 age group there were 31 pregnancies achieved successful from 79 transfers (39%). For patients over age 40, 8 of the 23 transfers were successful (35%).  In the donated oocytes group, 101 pregnancies resulted from 247 transfers (41% with an average of 1.7 embryos transferred).  For patients that had their embryos artificially collapsed, the results were better.  However, since this is a new technique, the number of cycles is small.

Overall, we are very pleased with the outcomes achieved with vitrified embryos.  We are optimistic that results will continue to improve.  The table above shows results for all cycles completed since the beginning of the vitrification program.  As our experience grows, so do our success rates.  Reviewing cycles of patients that had embryos warmed and transferred from just this year (Jan-Oct 2010), we see that the outcomes are exceptionally good, particularly  for patients whose embryos  were collapsed prior to vitrification.

At PFC we are continuing to vitrify all embryos by day 5 or 6 after oocyte retrieval if they are good or reasonable quality blastocysts.  We now routinely collapse any blastocyst with an expanding cavity.  These procedures have worked well.  Consequently, it has become necessary to reduce the number of embryos being transferred to avoid generating too many multiple pregnancies.  Our goal is to achieve a healthy singleton pregnancy in all patients; vitrification has allowed us to reduce the incidence of multiples by transferring just a single embryo most of the time.  For our 2009 fresh cycles, in patients under 35, 40% of the time we transferred just one embryo, and in patients using donor oocytes 60% of the transfers were a single embryo.  Vitrification has proved to be so successful that many patients have elected for a fresh single embryo transfer; virtually eliminating their risk of twins and knowing that their frozen embryos will be available should they be needed.

Title: The Fertile Kitchen Cookbook

Can diet influence fertility? Can altering your diet help you conceive? Is it true that you are what you eat (and so is your baby)?

At age 40 and after trying to conceive for over a year, Cindy Bailey and her husband Pierre Giauque were told that they were unlikely to conceive. With disconcerting medical test results and failure in conven tional treatment, alternative therapies seemed the best option. After trying a fertility-friendly diet, to their surprise, their son was conceived four months later.

The Fertile Kitchen is one couple’s story of overcoming the odds against conception while using common sense and easily executed measures to optimize health. Using fresh, high quality, organic ingredients, and reducing wheat and dairy; the couple developed a nutritional plan that they feel contributed to their success. These authors found that optimizing the basic ingredients for life, adjusting calories, carbohydrates, fats, and proteins into a regimen that has the potential to optimize pregnancy rates, should be considered in a given fertility plan.

Science is still catching up to medical concerns about fertility and diet. As an example of this emerging science, it is known that women with abnormal body fat levels, either high or low, suffer from lower pregnancy rates, and that improvement in body weight and body fat levels improves fertility rates…Certain types of animal protein are potentially problematic for fertility, whereas vegetable protein sources seem to carry less risk. Calorie source, simple sugar versus protein, makes a difference in treating anovulatory women. Irregular menstrual cycles can be optimized by changing diet. Omega-3 fatty acids are related to uterine artery perfusion pressures, and supplementation seems to provide some clinical improvement in these parameters. Studies are showing a role for B-complex vitamins, folic acid, and dietary fat in regulating ovulation.

It is unfortunate that some people have serious challenges to fertility that cannot be addressed with a change in diet. Diminished ovarian reserve, male factor, and tubal occlusion are problems that go beyond what can be remedied with diet alone. With that said, fertility treatment programs, regardless of the health issues, should include a healthy diet, as a good preventative measure for already healthy women wishing to conceive. The recipes in this book are easy to follow and the ingredients are amply available at most grocery stores.

Fertile Kitchen Media Kit (pdf)

— Philip Chenette, M.D.

Since Pacific Fertility Center came into existence in November of 1999, we have been offering genetic pre-screening of IVF embryos for couples with recurrent miscar- riage, repeated IVF implantation failure and sex selection for family balancing. For most of the last decade, a technology known as Fluorescent In-Situ Hybridization, or FISH has been used to screen embryos. FISH is employed to probe a cell removed from a Day 3 embryo to determine the chromosomal makeup for anywhere from three to twelve of the cell’s 23 pairs of chromosomes. With time, we, as well as everyone else in the reproductive genetic world, came to realize the serious limitations of this technology.

In the last 2-3 years, as the Human Genome Project has been completed and as more DNA-related biotechnologies have emerged to evaluate human genes, these methods are being utilized to analyze human embryos. The technology now available—the ability to analyze large numbers of genetic locations on each human chromosome, and quantify that genetic material, with the previously well-established techniques to amplify a single cell’s genetic material up to hundreds of thousands of copies—has allowed PGS to take a quantum leap forward. It is now possible to more accurately analyze all 23 chromosome pairs from a single embryo; not only to determine if the correct number of copies of each chromosome is present, but also to look at single gene mutations.

At the end of 2009, Pacific Fertility Center began working with a new biotech company called Gene Security Network, located in Redwood City (genesecurity.net). This company uses gene microarray technology to analyze amplified DNA from a single cell.

It then uses microchips to analyze 30,000 genetic loci in a quantitative manner. In addition, their unique technology allows us to compare the analysis of the embryos’ cells to the parent’s chromosomes to ensure that all the genes are being properly analyzed. It does appear that the error problems that plagued FISH technology have been overcome with this new, more sophisticated, method.

In October of 2009, Dr. Conaghan and I were invited to tour the GSN laboratory and see the technology in action. We met with David Johnson, the lead scientist at GSN, who explained the cell process; from the amplification of the DNA, to arranging the chromosomes on chips, to DNA analysis, to synthesizing the data generated with the parental genetic data to come up with a full analysis of that cell’s genome. In order to process the cells between the day of embryo biopsy (Day 3) and receive the results on the day of embryo transfer (Day 5), their technicians work around the clock in shifts. GSN has a very cold, clean room to replicate the single cells into multiple copies. They cannot allow any outside contamination, not even from a single cell. They videotape the cell duplicating process so if any errors subsequently arise, they have a video record of what the laboratory technician did. We found this to be very impressive. We also saw how the chips were coated with DNA and analyzed. We were shown the sophisticated software that generates the final report detailing the genetic makeup of each embryo from the cells in which they originated. All in all, the tour gave us great confidence in the quality control and scientific integrity at GSN.

Even with this 21st century technology, we continue to biopsy Day 3 embryos because it provides us with a 48 hours window to send the cells to the lab and complete the analysis in time for transfer. However, we have not yet found a way around the problem of mosa- icism. GSN and microarray technology appears to have largely solved the resolution error problem but it can only tell us what is in the chromosomal make-up of the single cell. It cannot tell us whether or not that cell represents what is truly going on with the rest of the embryo. We are currently looking at the possibility of biopsying Day 5 embryos. The set back would result in having to freeze these embryos due to the time constraint in analyzing the genetic material in time for fresh transfer. With all of the innovation occurring daily in the genetics field, we hope that this puzzle will be resolved.

— Carolyn Givens, M.D.

Previous Fertility Flash articles about PGS:
2 Methods of Gaining Info Prior to Implantation
PGD & PGS: Why Genetic Counseling is a Prerequisite
The Benefits and Pitfalls of PGS

These tests can be done by your primary care physician or gynecologist prior to consulting your Reproductive Endocrinologist:

• Day 3 FSH (follicle stimulating hormone) and Estradiol (Day 2-3 is acceptable)
• TSH (thyroid stimulating hormone)
• Prolactin
• Progesterone: 7 days prior to menses, this test is occasionally helpful
• Semen analysis

These tests may be useful based on each patient’s particular needs:

• Hysterosalpingogram (HSG) or documentation of tubal status
• Hysteroscopy
• Laparoscopy: The surgeon should be able to treat during this procedure, not just diagnosis.

The following treatments may be done, if indicated, for a limited number of cycles:

• IUI (intrauterine insemination)
• Clomiphene citrate (Clomid, Serophene)

At Pacific Fertility Center, we bring a complete team of specialists together to focus on your fertility situation. With extensive backgrounds as REI specialists, embryologists, nurses, marriage and family therapists and financial counselors, we develop a single, integrated solution to your medical, psychological and financial needs.

Please use our Ask the Experts resource if you have further questions.

– Philip Chenette, MD

These tests are best done through your Reproductive Endocrinologist (fertility specialist):

• Strict sperm morphology
  Strict morphology is a very specific method of evaluating the shape of sperm. Most laboratories do not use strict criteria thus potentially missing a sperm problem. Our laboratory is staffed with embryologists trained to analyze sperm with these strict criteria.
• Evaluation of ovarian reserve
  Evaluation of ovarian reserve includes family history, ultrasound to detect the antral follicle count (AFC), a cycle day 2-3 FSH and estradiol level (both must be done at the same time), Anti-mullerian Hormone AMH, and clinical and family history.  An REI can bring all of these assessments together into one consistent picture of a woman’s ovarian reserve.
• Ultrasound
  A pelvic ultrasound is a very useful test when it is done at the appropriate time in the menstrual cycle. A few days prior to ovulation an ultrasound can evaluate ovulation, follicle growth, endometrial thickness and pattern, polyps, and fibroids. During menses is the best time to evaluate the ovary for cysts and endometriosis.
• Genetic testing
  Genetic testing is important in women with premature menopause and multiple miscarriages and men with very low sperm counts.  Patients with a family history of a genetic disease can use genetic testing to determine if they are carriers of the disease.  Universal genetic testing (Counsyl, www.counsyl.com) can be used to assess risk for certain genetic illnesses that run in families. If detected, Preimplantation Genetic Diagnosis (PGD) can help prevent genetic illness in your child.
• Insulin
  Women who have irregular periods and have been told they have Polycystic Ovary Syndrome (PCOS) should be evaluated by an REI.  Testing can lead to more effective treatment.

Treatments by a fertility specialist

The advanced training of an REI is helpful to provide the most successful treatments for infertility.

Some of these treatments include:

• In vitro fertilization with embryo transfer (IVF, or IVF/ET),
• Fertility preservation
• Egg freezing
• Intracytoplasmic sperm injection (ICSI)
• Preimplantation genetic diagnosis (PGD)
• Ovulation induction
• Intrauterine insemination

A specialist is able to evaluate simpler treatments and finely tune them to make them more effective. For example, a specialist can monitor ovulation induction with clomiphene (Clomid) with ultrasound and blood tests. The vaginal ultrasound can be used to assess follicle development and endometrial pattern and thickness. Intrauterine inseminations can be done to bypass hostile mucus caused by clomiphene. The specialist can also help decide when to stop a particular treatment and/or proceed with more.

Alternative medications like letrozole (Femara) are just as effective as clomiphene but have fewer side effects.  Since letrozole is not approved by the FDA for marketing for fertility use, its use is generally restricted to specialty clinics, that is, REIs.

Gonadotropins, the injectable drugs, for example Follistim, Gonal-F, Bravelle, and Menopur, are potent stimulants to the ovary.  They are designed to produce multiple follicles, in order to improve pregnancy rates.  Due to the risk of multiple pregnancy and overstimulation of the ovaries, the medications should be used only by experts in the field.  Most of these treatments are performed by REIs in the United States.

At Pacific Fertility Center, we bring a complete team of specialists together to focus on your fertility situation. With extensive backgrounds as REI specialists, embryologists, nurses, marriage and family therapists and financial counselors, we develop a single, integrated solution to your medical, psychological and financial needs.

Please use our Ask the Experts resource if you have further questions.

– Philip Chenette, MD

One of the biggest challenges we face as fertility medicine specialists is how to do more to help our least-likely-to-succeed patients. What I mean here is the 42-and-over age group, patients with high FSH levels (decreased ovarian reserve), patients with very low responses to fertility medications, or those with very poor quality eggs. Some patients have a combination of the above which leads to a really dim prospect of having a baby with their own eggs.

Some people get the impression that fertility clinics avoid these patients like they have a communicable disease. They get the impression that we try to cherry pick patients to keep success rates high and make the CDC stats look good.  My impression from talking to my colleagues across the country and certainly from our own practice is that we do not try to discourage patients with poor possibilities from making a consult appointment and discussing treatment options. We all have such patients. In fact, we have so many of them at PFC, I don’t think we would have many patients at all if we tried to pre-select our best prognosis patients for IVF. When it comes to treatment, although there are challenges and sometimes the rewards are few, we don’t just throw up our hands and give up. We try to come up with a strategy to achieve the goal, looking at the emotional reserves and financial resources we have to work with, and start by making a plan.

Sometimes that plan will be to try a couple of cycles of low-tech approach, like just intrauterine insemination or Clomid + insemination, or a mid-level approach, like injections of FSH along with  insemination. We would see how things go and play it by ear from there. Sometimes, the plan will be to blast ahead to the big guns, full steam ahead to IVF. Sometimes, it’s counseling with our marriage and family therapist to begin the discussion: are we ready to move on to donor eggs? Sometimes it’s a sequence of all of the above. There really is no one plan for any one person. It’s just too complex to say one size fits all.

A certain percentage, even of the-less-likely-to-succeed patients will get pregnant with their own eggs and go on to deliver a healthy baby. The remainder may be faced with a tough decision. Do we just stop here and live child-free?  There are certain perks to that plan (sleeping in on the weekends, eating in nicer restaurants, adult vacations to name just a couple) but most people want to have a family no matter what or how. So then there is the adoption vs. egg donation question. There is no right or wrong choice here, either: just choices.